28320 Federal Register / Vol. 82, No.
118 / Wednesday, June 21, 2017 / Notices
FEDERAL MARITIME COMMISSION
Notice of Agreement Filed
The Commission hereby gives notice
of the filing of the following agreement
under the Shipping Act of 1984.
Interested parties may submit comments
on the agreement to the Secretary,
Federal Maritime Commission,
Washington, DC 20573, within twelve
days of the date this notice appears in
the Federal Register. A copy of the
agreement is available through the
Commission’s Web site (www.fmc.gov)
or by contacting the Office of
Agreements at (202)–523–5793 or
tradeanalysis@fmc.gov.
Agreement No.: 011284–077.
Title: Ocean Carrier Equipment
Management Association Agreement.
Parties: Alianca Navegacao e Logistica
Ltda.; APL Co. Pte Ltd.; American
President Lines, Ltd.; Maersk Line A/S;
CMA CGM, S.A.; COSCO Shipping Co.,
Ltd; Evergreen Line Joint Service
Agreement; Hamburg-Süd; Hapag-Lloyd
AG; Hapag-Lloyd USA LLC; Ltd.;
Hyundai Merchant Marine Co. Ltd.;
Kawasaki Kisen Kaisha, Ltd.;
Mediterranean Shipping Company, S.A.;
Mitsui O.S.K. Lines Ltd.; Nippon Yusen
Kaisha Line; Orient Overseas Container
Line Limited; United Arab Shipping
Limited; Yang Ming Marine Transport
Corp.; and Zim Integrated Shipping
Services, Ltd.
Filing Party: Jeffrey F, Lawrence, Esq.
and Donald J. Kassilke, Esq.; Cozen
O’Connor; 1200 Nineteenth Street NW.,
Washington, DC 20036.
Synopsis: The amendment deletes
parties to the agreement; revises the
affiliations of certain members; and
reflects updates to the name and address
of a party.
Agreement No.: 012206–003.
Title: Grimaldi/‘‘K’’ Line Space
Charter Agreement.
Parties: Grimaldi Deep Sea S.P.A.;
Grimaldi Euromed S.p.A.; and Kawasaki
Kisen Kaisha, Ltd.
Filing Party: John P. Meade, General
Counsel; ‘‘K’’ Line America, Inc.; 6199
Bethlehem Road; Preston, MD 21655.
Synopsis: The amendment updates
the Agreement to correct clerical errors
and expands the geographic scope of the
Agreement.
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Agreement No.: 012486.
Title: Crowley/King Ocean Vessel
Sharing Agreement.
Parties: Crowley Latin America
Services, LLC and King Ocean Services
Limited, Inc.
Filing Party: Wayne Rohde, Esq.;
Cozen O’Connor; 1200 Nineteenth Street
NW., Washington, DC 20036.
VerDate Sep<11>2014 19:12 Jun 20, 2017 Jkt 241001
Synopsis: The agreement authorizes
the parties to share vessels in the trade
between Florida on the one hand and
Costa Rica and Panama on the other
hand.
By Order of the Federal Maritime
Commission.
Dated: June 16, 2017.
Rachel E. Dickon,
Assistant Secretary.
[FR Doc. 2017–12946 Filed 6–20–17; 8:45 am]
BILLING CODE 6731–AA–P
FEDERAL RESERVE SYSTEM
Change in Bank Control Notices;
Acquisitions of Shares of a Bank or
Bank Holding Company
The notificants listed below have
applied under the Change in Bank
Control Act (12 U.S.C. 1817(j)) and
§ 225.41 of the Board’s Regulation Y (12
CFR 225.41) to acquire shares of a bank
or bank holding company. The factors
that are considered in acting on the
notices are set forth in paragraph 7 of
the Act (12 U.S.C. 1817(j)(7)).
The notices are available for
immediate inspection at the Federal
Reserve Bank indicated. The notices
also will be available for inspection at
the offices of the Board of Governors.
Interested persons may express their
views in writing to the Reserve Bank
indicated for that notice or to the offices
of the Board of Governors. Comments
must be received not later than July 7,
2017.
A. Federal Reserve Bank of Kansas
City (Dennis Denney, Assistant Vice
President) 1 Memorial Drive, Kansas
City, Missouri 64198–0001:
1. Erika R. Feingold Irrevocable
Insurance Trust dated August 1, 1985,
Chad M. Feingold Irrevocable Insurance
Trust dated August 1, 1985, Chad M.
Feingold Grantor Trust dated August 24,
1998, Erika R. Feingold Grantor Trust,
Mark A. Morgan Family Irrevocable
Trust dated January 29, 1998, Thomas
S. Morgan Family Irrevocable Trust
dated January 30, 1998, Mia M.
Velasquez Irrevocable Trust dated
October 30, 2000, Avi Velasquez
Irrevocable Trust dated June 2, 2003,
Marley Blake Velasquez Irrevocable
Trust dated December 13, 2004, all of
Overland Park, Kansas, and Marilyn R.
O’Halloran Revocable Trust, Leawood,
Kansas, of which Robert J. O’Halloran,
Overland Park, Kansas, serves as trustee
or co-trustee, and Marilyn R.
O’Halloran, individually as co-trustee of
the Marilyn R. O’Halloran Revocable
Trust; to retain voting shares and be
approved as members of the O’Halloran
PO 00000 Frm 00027 Fmt 4703 Sfmt 4703 E:\FR\FM\21JNN1.SGM
control group, which own voting shares
of Valley View Bancshares, Inc.,
Overland Park, Kansas, and indirectly
owns Security Bank of Kansas City,
Kansas City, Kansas.
Board of Governors of the Federal Reserve
System, June 16, 2017.
Yao-Chin Chao,
Assistant Secretary of the Board.
[FR Doc. 2017–12930 Filed 6–20–17; 8:45 am]
BILLING CODE 6210–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[CDC–2017–0028, Docket Number NIOSH–
290]
Draft Current Intelligence Bulletin: The
Occupational Exposure Banding
Process: Guidance for the Evaluation
of Chemical Hazards; Reopening of
Comment Period
AGENCY: National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice and reopening of
comment period.
SUMMARY: On March 15, 2017 the
National Institute for Occupational
Safety and Health (NIOSH) of the
Centers for Disease Control and
Prevention (CDC), published a notice in
the Federal Register [82 FR 13809]
announcing the availability of a draft
Current Intelligence Bulletin entitled
The Occupational Exposure Banding
Process: Guidance for the Evaluation of
Chemical Hazards for public comment.
NIOSH convened a public meeting in
Cincinnati, Ohio on Tuesday, May 23,
2017 to discuss the document. The draft
document can be found at
www.regulations.gov. by entering CDC–
2017–0028 in the search field and
clicking ‘‘Search.’’ Written comments
were to be received by June 13, 2017. In
response to a request from an interested
party, NIOSH is announcing the
reopening of the comment period.
DATES: Electronic or written comments
must be received by July 21, 2017.
FOR FURTHER INFORMATION CONTACT:
Melissa Seaton, NIOSH, Education and
Information Division, 1090 Tusculum
Avenue, MS C–32, Cincinnati, OH
45226, telephone (513) 533–8248, Fax
(513) 533–8230 (not toll free numbers),
email MSeaton@cdc.gov.
21JNN1
 Federal Register / Vol. 82, No. 118 / Wednesday, June 21, 2017 / Notices
ADDRESSES: You may submit comments,
identified by CDC–2017–0028 and
Docket Number NIOSH–290, by either
of the following two methods:
• Federal eRulemaking Portal: http://
www.regulations.gov. Follow the
instructions for submitting comments.
• Mail: National Institute for
Occupational Safety and Health, NIOSH
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, Ohio 45226–1998.
John Howard,
Director, National Institute for Occupational
Safety and Health, Centers for Disease Control
and Prevention.
[FR Doc. 2017–12942 Filed 6–20–17; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2017–N–2769]
Development of New Tuberculosis
Treatment Regimens—Scientific and
Clinical Trial Design Considerations;
Public Workshop; Request for
Comments
AGENCY: Food and Drug Administration,
HHS.
ACTION: Notice of public workshop;
request for comments.
SUMMARY: The Food and Drug
Administration (FDA, the Agency, or
we) is/are announcing a public
workshop regarding scientific and
clinical trial design considerations for
the development of new tuberculosis
(TB) treatment regimens. This public
workshop is intended to provide
information for and gain perspective
from health care providers, other U.S.
Government Agencies, academic
experts, industry, and other
stakeholders regarding scientific and
clinical trial design considerations
related to the development of new TB
regimens.
DATES: The public workshop will be
held on July 19, 2017, from 8:30 a.m. to
5 p.m. Submit either electronic or
written comments on this public
workshop by August 1, 2017. See the
SUPPLEMENTARY INFORMATION section for
registration date and information. The
workshop draft agenda will be made
asabaliauskas on DSKBBXCHB2PROD with NOTICES
available at https://www.fda.gov/Drugs/
NewsEvents/ucm548365.htm prior to
the meeting.
ADDRESSES: The public workshop will
be held at FDA’s White Oak Campus,
10903 New Hampshire Ave., Building
31 Conference Center, the Great Room
(Rm. 1503), Silver Spring, MD 20993.
VerDate Sep<11>2014 19:12 Jun 20, 2017 Jkt 241001
Entrance for the public workshop
participants (non-FDA employees) is
through Building 1 where routine
security check procedures will be
performed. For parking and security
information, please refer to https://
www.fda.gov/AboutFDA/
WorkingatFDA/BuildingsandFacilities/
WhiteOakCampusInformation/
ucm241740.htm.
You may submit comments as
follows. Please note that late, untimely
filed comments will not be considered.
Electronic comments must be submitted
on or before August 1, 2017. The https://
www.regulations.gov electronic filing
system will accept comments until
midnight eastern time on August 1,
2017. Comments received by mail/hand
delivery/courier (for written/paper
submissions) will be considered timely
if they are postmarked or the delivery
service acceptance receipt is on or
before that date.
Electronic Submissions
Submit electronic comments in the
following way:
• Federal eRulemaking Portal:
https://www.regulations.gov. Follow the
instructions for submitting comments.
Comments submitted electronically,
including attachments, to https://
www.regulations.gov will be posted to
the docket unchanged. Because your
comment will be made public, you are
solely responsible for ensuring that your
comment does not include any
confidential information that you or a
third party may not wish to be posted,
such as medical information, your or
anyone else’s Social Security number, or
confidential business information, such
as a manufacturing process. Please note
that if you include your name, contact
information, or other information that
identifies you in the body of your
comments, that information will be
posted on https://www.regulations.gov.
• If you want to submit a comment
with confidential information that you
do not wish to be made available to the
public, submit the comment as a
written/paper submission and in the
manner detailed (see ‘‘Written/Paper
Submissions’’ and ‘‘Instructions’’).
Written/Paper Submissions
Submit written/paper submissions as
follows:
• Mail/Hand delivery/Courier (for
written/paper submissions): Dockets
Management Staff (HFA–305), Food and
Drug Administration, 5630 Fishers
Lane, Rm. 1061, Rockville, MD 20852.
• For written/paper comments
submitted to the Dockets Management
Staff, FDA will post your comment, as
well as any attachments, except for
PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 E:\FR\FM\21JNN1.SGM
28321
information submitted, marked and
identified, as confidential, if submitted
as detailed in ‘‘Instructions.’’
Instructions: All submissions received
must include the Docket No. FDA–
2017–N–2769 for ‘‘Development of New
Tuberculosis Treatment Regimens—
Scientific and Clinical Trial Design
Considerations; Public Workshop;
Request for Comments.’’ Received
comments, those filed in a timely
manner (see ADDRESSES), will be placed
in the docket and, except for those
submitted as ‘‘Confidential
Submissions,’’ publicly viewable at
https://www.regulations.gov or at the
Dockets Management Staff between 9
a.m. and 4 p.m., Monday through
Friday.
• Confidential Submissions—To
submit a comment with confidential
information that you do not wish to be
made publicly available, submit your
comments only as a written/paper
submission. You should submit two
copies total. One copy will include the
information you claim to be confidential
with a heading or cover note that states
‘‘THIS DOCUMENT CONTAINS
CONFIDENTIAL INFORMATION.’’ The
Agency will review this copy, including
the claimed confidential information, in
its consideration of comments. The
second copy, which will have the
claimed confidential information
redacted/blacked out, will be available
for public viewing and posted on
https://www.regulations.gov. Submit
both copies to the Dockets Management
Staff. If you do not wish your name and
contact information to be made publicly
available, you can provide this
information on the cover sheet and not
in the body of your comments and you
must identify this information as
‘‘confidential.’’ Any information marked
as ‘‘confidential’’ will not be disclosed
except in accordance with 21 CFR 10.20
and other applicable disclosure law. For
more information about FDA’s posting
of comments to public dockets, see 80
FR 56469, September 18, 2015, or access
the information at: https://www.gpo.gov/
fdsys/pkg/FR-2015-09-18/pdf/2015-
23389.pdf.
Docket: For access to the docket to
read background documents or the
electronic and written/paper comments
received, go to https://
www.regulations.gov and insert the
docket number, found in brackets in the
heading of this document, into the
‘‘Search’’ box and follow the prompts
and/or go to the Dockets Management
Staff, 5630 Fishers Lane, Rm. 1061,
Rockville, MD 20852.
FOR FURTHER INFORMATION CONTACT: Lori
Benner and/or Jessica Barnes, Center for
21JNN1